Can a Blood Test Replace a Colonoscopy? What the 2026 Update Means

Short answer: usually no. The 2026 American Cancer Society update did not make a blood test an equal stand-in for colonoscopy for colorectal cancer screening.

What changed is narrower than some headlines suggest. ACS added blood-based screening as a limited, non-preferred option for some average-risk adults age 45 and older who decline or do not complete preferred screening tests. For most readers, colonoscopy and stool-based screening are still the main options to discuss with a clinician.

What changed in 2026

In its May 27, 2026 update, ACS kept the core age guidance the same: average-risk adults should start colorectal cancer screening at 45. Screening is generally recommended through 75 if a person is in good health and has a life expectancy of more than 10 years. From 76 through 85, the decision should be individualized. After 85, screening is generally not recommended.

The new part is that blood-based screening was added to the menu, but only in a limited role. The formal guideline says blood-based tests are for average-risk adults who decline or do not complete a preferred high-sensitivity stool test or a structural exam such as colonoscopy.

Why that does not mean blood tests replaced colonoscopy

ACS still treats colonoscopy and stool-based tests as the preferred screening routes. The reason is practical: screening is not just about finding cancer that is already present. Some preferred tests can also find advanced precancerous growths, and colonoscopy can remove polyps during the same procedure.

The 2026 change is a guideline update based on a targeted evidence review, test-performance data, and modeling studies. It did not conclude that blood tests work as well as colonoscopy or established stool testing. Instead, the guideline says blood-based tests are less effective at finding advanced precancerous lesions and some very early cancers, so they are considered a backup option when preferred tests are not being completed.

What the FDA approval does and does not mean

The FDA approval page for the Shield blood test says it is intended for adults 45 and older at average risk who need colorectal cancer screening. It is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in people at higher risk.

The FDA also says a negative result does not rule out colorectal cancer. In the trial reviewed by FDA, the test detected colorectal cancer in 83% of people with cancer in the study population, but performance was lower for advanced precancerous lesions. That helps explain why a normal blood test should not be treated as a permanent all-clear.

If a blood test is positive, colonoscopy is still the next step

A positive blood test does not finish screening. It starts the follow-up.

ACS and CDC both say an abnormal result on a non-colonoscopy screening test should be followed by a timely colonoscopy to complete the screening process. The guideline publication says that follow-up colonoscopy should ideally happen within 6 months.

That is a big reason a blood test does not fully replace colonoscopy. If the result is abnormal, colonoscopy is still needed to look directly at the colon and remove or biopsy anything suspicious.

Who should not rely on a blood test as a substitute

Blood-based screening is meant for people at average risk who have no symptoms.

It is not meant to replace diagnostic evaluation if you already have warning signs such as blood in the stool, a lasting change in bowel habits, unexplained weight loss, or ongoing belly pain. It is also not meant for people with a personal history of colorectal cancer or adenomas, inflammatory bowel disease, certain family-history patterns, or hereditary cancer syndromes. Those situations can call for a different screening or surveillance plan.

If you have severe abdominal pain, heavy rectal bleeding, black stools, or cannot pass stool or gas, seek urgent medical care rather than relying on a screening test.

Medicare coverage basics

For people on Medicare, the consumer-facing coverage page says Part B covers a blood-based biomarker screening test for colorectal cancer once every 3 years if certain conditions are met. The page describes the benefit as applying to people ages 45 through 85 who have no symptoms of colorectal disease and are at average risk.

Medicare says you generally pay nothing for the test if your provider accepts assignment. Coverage details can still depend on provider arrangements and any other insurance you have, so it is smart to confirm the exact coverage and follow-up steps before scheduling. A positive result still means colonoscopy is needed, so ask how that next step would be arranged and covered.

Questions to ask before you choose

Am I actually average risk, or does my personal or family history change my screening options?
Among the preferred tests, which choice fits my situation best right now?
If I choose a blood test, what is the plan and timeline for colonoscopy if it comes back positive?
If the blood test is negative, when would I need screening again?
How will Medicare or my insurance handle the test itself and any follow-up colonoscopy?

Bottom line

The 2026 ACS update widened the screening menu, but it did not make blood tests the new first choice for most people. For average-risk adults who have been putting off screening, a blood test may be better than doing nothing. But colonoscopy and stool-based screening remain the preferred routes, and a positive blood test still leads to colonoscopy.

If you are 45 or older and have not started colorectal cancer screening, the most important next step is to talk with a clinician about which option you are actually willing and able to complete.

Sources

Editorial note: Weence articles are researched from cited public-health, medical, regulatory, journal, and reputable news sources and may be drafted with AI assistance. They are checked for source support, clarity, and safety guardrails before publication.

This article is for general informational purposes only and is not medical advice. Research findings can be early or incomplete, and health guidance can change. Always talk with a qualified healthcare professional about personal symptoms, diagnosis, medications, vaccines, screenings, or treatment decisions. If you think you may have a medical emergency, call emergency services right away.